^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PDE5A (Phosphodiesterase 5A)

    i
    Other names: PDE5A, Phosphodiesterase 5A, CGMP-Specific 3',5'-Cyclic Phosphodiesterase, Phosphodiesterase 5A, CGMP-Specific, CGB-PDE, PDE5, CGMP-Binding CGMP-Specific 3',5'-Cyclic Nucleotide Phosphodiesterase, CGMP-Binding CGMP-Specific Phosphodiesterase, CGMP-Specific Phosphodiesterase Type 5A, CGMP-Specific Phosphodiesterase PDE5A2, Phosphodiesterase Isozyme 5, CN5A
    2ms
    Pan-Cancer Analysis of Cyclic Nucleotide Phosphodiesterases (PDEs) Expression, Variation, and Prognostic Significance. (PubMed, ACS Omega)
    Five differentially expressed PDEs (PDE5A, PDE6D, PDE8A, PDE8B, and PDE9A) were identified as independent prognostic factors for patients with pan-cancer in both the training and testing cohorts. To our knowledge, this is the first study to construct a PDE signature in pan-cancer and to highlight the pivotal role of PDE4D in LIHC (liver hepatocellular carcinoma).
    Journal • Pan tumor
    |
    PDE5A (Phosphodiesterase 5A)
    4ms
    PDE5A+ cancer-associated fibroblasts enhance immune suppression in gastric cancer. (PubMed, Gut)
    Our study elucidates the intricate role of PDE5A+ CAFs in shaping the immunosuppressive TME in GC, providing mechanistic insights and therapeutic potential for combating this aggressive malignancy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • LAG3 (Lymphocyte Activating 3) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • PDE5A (Phosphodiesterase 5A)
    7ms
    Genetically proxied inhibition of Phosphodiesterase-5 and cancer risks: A drug-target Mendelian randomization analysis. (PubMed, Sci Rep)
    We found an protective effect of genetically proxied PDE5 inhibition on CRC and GC risk. Our drug target MR analyses provide genetic evidence in predicting long-term safety profiles of PDE5 inhibitors on cancer risk and highlight the potential of drug repurposing in CRC and GC.
    Journal
    |
    PDE5A (Phosphodiesterase 5A)
    8ms
    Investigating SMYD3 role during oocyte maturation in a 3D follicle-enclosed oocyte in vitro model in sheep. (PubMed, Front Cell Dev Biol)
    SMYD3 is identified as a key modulator of oocyte maturation, orchestrating meiotic progression through CDC25A regulation and interacting with hCG-driven somatic signaling. These findings highlight SMYD3 as a critical determinant of late oogenesis and a potential target for enhancing oocyte competence in assisted reproductive technologies.
    Preclinical • Journal
    |
    MAPK1 (Mitogen-activated protein kinase 1) • PDE5A (Phosphodiesterase 5A) • SMYD3 (SET And MYND Domain Containing 3) • CDC25A (Cell Division Cycle 25A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    1year
    Mendelian randomization analysis of plasma proteins reveals potential novel tumor markers for gastric cancer. (PubMed, Sci Rep)
    Pathway enrichment analysis of gene expression associated with these 14 plasma proteins, using GO and KEGG pathways, revealed that CHST15, L1CAM, FTMT, and PMM2 may serve as protective factors against gastric cancer, while ABO, FAM3D, FAM3B, ADH7, MAP1LC3A, PGLYRP1, PDE5A, GLUL, NFE2L1, and MAFG may contribute to gastric cancer pathogenesis. These results highlight the complex biological interactions between plasma proteins and tumorigenesis, providing valuable insights for preventive and therapeutic strategies in gastric malignancy management.
    Journal
    |
    L1CAM (L1 cell adhesion molecule) • PDE5A (Phosphodiesterase 5A) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha) • PMM2 (Phosphomannomutase 2)
    1year
    Unveiling the substantial role of rutin in the management of drug-induced nephropathy using network pharmacology and molecular docking. (PubMed, Int Immunopharmacol)
    The revelation of mode of action of bioactive constituent rutin against drug-induced nephropathy provides a theoretical basis for designing more promising compounds in future for treatment of nephropathy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • MCL1 (Myeloid cell leukemia 1) • KDR (Kinase insert domain receptor) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PRKCH (Protein Kinase C Eta) • IL2 (Interleukin 2) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • SYK (Spleen tyrosine kinase) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • IR (Insulin receptor) • MMP9 (Matrix metallopeptidase 9) • SERPINE1 (Serpin Family E Member 1) • CDK1 (Cyclin-dependent kinase 1) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2) • MAPT (Microtubule Associated Protein Tau) • NOX4 (NADPH Oxidase 4) • PDE5A (Phosphodiesterase 5A) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha) • PRKCA (Protein Kinase C Alpha) • PRKCB (Protein Kinase C Beta) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2) • MMP3 (Matrix metallopeptidase 3) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    1year
    Network pharmacology and metabolomics elucidate the underlying effects and mechanisms of maackiain against endometrial cancer. (PubMed, Biochem Biophys Res Commun)
    These findings underlined that MA has anti-EC potential by modulating multiple targets including PLA2G10, PDE4D, and PDE5A, inhibiting EC cell proliferation, inducing G2/M phase arrest, and causing metabolic shifts. This study provides theoretical support for advanced experimental research on its clinical applications.
    Journal • Metabolomic study
    |
    TP53 (Tumor protein P53) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • PDE5A (Phosphodiesterase 5A) • CCNB1 (Cyclin B1)
    |
    TP53 expression
    over1year
    Exploring the oncogenic role of RGS19 in bladder cancer progression and prognosis. (PubMed, Acta Histochem)
    Pathway analysis suggested RGS19 acts through the cGMP-PKG signaling pathway, validated by altered expression of soluble guanylate cyclase (sGC), protein kinase G (PKG1), phosphodiesterase 5 A (PDE5A), vasodilator-stimulated phosphoprotein (VASP), and phosphorylated VASP (p-VASP) upon RGS19 knockdown. These results highlight RGS19 as a potential biomarker and therapeutic target in BLCA.
    Journal
    |
    PDE5A (Phosphodiesterase 5A)
    over1year
    Pharmacological properties of extracts and prenylated isoflavonoids from the fruits of Osage orange (Maclura pomifera (Raf.) C.K.Schneid.). (PubMed, Fitoterapia)
    Different molecular mechanisms are discussed, including osajin‑copper complexation and binding to quadruplex DNA. An overview of the mechanism of action of the prenylated isoflavones from Osage orange is presented, with the objective to promote their knowledge and to raise opportunities to better exploit the fruits of Osage orange, abundant but largely neglected at present.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PDE5A (Phosphodiesterase 5A)
    almost2years
    Potential drug targets for tumors identified through Mendelian randomization analysis. (PubMed, Sci Rep)
    Circulating PDE5A is associated with increased risk of CRC, while circulating MIA is associated with decreased risk of NSCLC. These findings suggest that four proteins may serve as biomarkers for cancer prevention and as potential drug targets that could be expected for approval.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PDE5A (Phosphodiesterase 5A) • S100A16 (S100 Calcium Binding Protein A16)
    |
    EGFR positive
    almost2years
    Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy. (PubMed, Signal Transduct Target Ther)
    Clinically, CRC patients exhibiting high MEX3A expression and low PDE5A expression have the poorest overall survival. Our findings reveal a collaboration between MEX3A and circMPP6 in the regulation of mRNA decay through triggering the PBs aggregation, which provides prognostic markers and/or therapeutic targets for CRC.
    Journal
    |
    PDE5A (Phosphodiesterase 5A) • MEX3A (Mex-3 RNA Binding Family Member A)
    2years
    Hsa_circ_0092355 Accelerates Papillary Thyroid Cancer Progression by Regulating the miR-543/PDE5A Pathway. (PubMed, Horm Metab Res)
    Furthermore, miR-543 suppresses PTC progression by downregulating PDE5A expression. Our findings suggest that the PTC tumor promoter hsa_circ_0092355 may promote carcinogenesis by controlling the miR-543/PDE5A pathway.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • MIR543 (MicroRNA 543) • PDE5A (Phosphodiesterase 5A)